We observed that IGFBP2 protein levels correlated with resistance to MAPKi in several BRAFV600-mutant melanoma cell lines, and is associated with poor prognosis in primary melanomas (Supplementary Fig. 8b, Fig. 5f and Supplementary Fig. 10a, b). This evidence concerns the gene IGFBP2 and melanoma.